Company profile
Phathom Pharmaceuticals, Inc.
NASDAQ: PHAT · Healthcare · Biotechnology
#299 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
47DFH 40DQ 54GM —SS 63
v0.1 · 55/100 weight · provisional
↑ filing timeliness, revenue growth (YoY) · ↓ disclosure history, balance-sheet leverage
Methodology →Revenue TTM
$239.7M
Rev growth YoY (TTM)
+110.2%
Net income (FY)
-$221.2M
Employees
371
as of 2026-08-10
Market cap
$691.7M
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$175.1M$175.1M2025
Net income-$221.2M-$221.2M2025
Operating income-$160.0M-$160.0M2025
Total assets$259.1M$259.1M2025
Liabilities$697.3M$697.3M2025
Equity-$438.2M-$438.2M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Phathom Pharmaceuticals, Inc.’s revenue?
Phathom Pharmaceuticals, Inc. booked $175.1M in FY2025 revenue, growing 217% year over year — faster than 90% of Healthcare companies we track, at a -126.3% net margin.
Peers · Healthcare
Maravai LifeSciences Holdings, Inc.53DStoke Therapeutics, Inc.60CHeartflow, Inc. Common Stock44DMedicine Man Technologies, Inc.——Syndax Pharmaceuticals, Inc.52DREGENXBIO Inc.54DNeighbors
Morris →Key facts
CEOSteven L. Basta
SectorHealthcare
IndustryBiotechnology
HeadquartersFlorham Park, NJ
ExchangeNASDAQ: PHAT
Employees371
IPO date2019-10-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.